LRRK2 and Parkinson disease: Mutations in LRRK2 cause it to become a risk factorfor Parkinson’s disease (PD), and the pathological functionsof LRRK2 correlate mainly with aberrant kinase activity.1−6 The modulation of LRRK2 kinase activity via the design of small-moleculeinhibitors has thus been a central focus for treating PD,7−10 and most of the studies so far have focused on kinase inhibitors.